Vertaling van "age and years of service " (Nederlands → Frans) :

As part of this change, Novartis, supported by the Swiss Pension Fund, will make transitional payments, which vary according to the member’s age and years of service.
Ces changements impliquent que Novartis, soutenu par la Caisse de pensions, effectue des versements de primes de transfert qui varient en fonction de l’âge de l’assuré et des années de service.

55. Mandelblatt J, Saha S, Teutsch S, Hoerger T, Siu AL, Atkins D, et al. The costeffectiveness of screening mammography beyond age 65 years: a systematic review for the U.S. Preventive Services Task Force.
54. Mandelblatt J, Saha S, Teutsch S, Hoerger T, Siu AL, Atkins D, et al. The costeffectiveness of screening mammography beyond age 65 years: a systematic review for the U.S. Preventive Services Task Force.

16. Miller A, Baines C, Wall C. Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50-59 years.
17. Miller A, Baines C, Wall C. Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50-59 years.

Finally, the Board proposes the re-election of Dr. Daniel Vasella and Marjorie M.T. Yang, each for a three-year term, and Hans-Joerg Rudloff for a one-year term (as he will reach the age limit).
Enfin, le Conseil d’administration propose de réélire le D r Daniel Vasella et Marjorie M.T. Yang pour un mandat de trois ans chacun et Hans-Joerg Rudloff pour un mandat d’un an (car il sera atteint par la limite d’âge).

This approval was based on data showing Xolair reduced asthma attacks in this age group by 34% at 24 weeks and 50% at one year.
Cette autorisation repose sur des résultats montrant que Xolair réduisait les accès d’asthme chez ce groupe d’âges de 34% sur 24 semaines et de 50% sur un an.

Ilaris (ACZ885, canakinumab) (USD 6 million) is a biologic medicine approved in more than 40 countries to treat adults and children aged four years and older suffering from cryopyrin-associated periodic syndrome (CAPS), a group of rare auto-inflammatory disorders that affect approximately one in one million people.
Ilaris (ACZ885, canakinumab) (USD 6 millions), est un médicament biologique autorisé dans plus de quarante pays pour traiter les adultes et les enfants de plus de quatre ans souffrant du syndrome périodique associé à la cryopirine (CAPS), un groupe de maladies auto-inflammatoires qui touche environ une personne sur un million.

The CHMP gave a positive opinion for the approval of tobramycin inhalation powder (TOBI Podhaler) for the suppressive therapy of chronic pulmonary infection due to Pseudomonas aeruginosa in adult and children age six years and older with cystic fibrosis.
inhalation (TOBI Podhaler) pour le traitement suppressif de l’infection pulmonaire chronique due au pseudomonas aeruginosa chez les adultes et les enfants de plus de six ans atteints de fibrose cystique.

Ilaris (ACZ885) (USD 6 million), is the first medicine to treat adults and children aged four years and older suffering cryopyrin-associated periodic syndrome (CAPS), a group of rare autoinflammatory disorders that affect one in one million people.
Ilaris (ACZ885) (USD 6 million), est le premier médicament pour traiter les adultes et les enfants de plus de quatre ans souffrant du syndrome périodique associé à la cryopirine (CAPS), un groupe de maladies auto-inflammatoires qui touche une personne sur un million.

Table 20: Invasive breast cancer and in situ breast cancer amongst women aged 40-49, observed and estimated incidence rate / 100.000 women per year in Flanders (Belgium) (1999-2006)
Table 20 : Invasive breast cancer and in situ breast cancer amongst women aged 40-49, observed and estimated incidence rate / 100.000 women per year in Flanders (Belgium) (1999-2006)

2010: Delivering on strategic priorities Novartis expects 2010 to be a year of significant progress in implementing its strategy to meet the growing needs of patients and aging societies worldwide through its healthcare portfolio.
En 2010, créer de la valeur grâce aux priorités stratégiques Novartis prévoit que 2010 verra des progrès sensibles dans la mise en œuvre de sa stratégie consistant à satisfaire les besoins croissants des malades et des populations vieillissantes du monde entier grâce à son portefeuille de soins de santé.